YM BioSciences Inc, an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, reported that Oncoscience AG, the European licensee of nimotuzumab from YM's subsidiary, CIMYM BioSciences Inc., has withdrawn its application to the European Medicines Agency for marketing authorization of nimotuzumab.
The details can be read here.
No comments:
Post a Comment